-
公开(公告)号:US20240091352A1
公开(公告)日:2024-03-21
申请号:US18175894
申请日:2023-02-28
Applicant: GENMAB A/S
Inventor: Esther BREIJ , David SATIJN , Edward Norbert VAN DEN BRINK , Dennis VERZIJL , Rob N. DE JONG , Paul PARREN , Riemke VAN DIJKHUIZEN RADERSMA
IPC: A61K39/395 , A61K47/68 , C07K16/28 , C07K16/30
CPC classification number: A61K39/39558 , A61K47/6801 , A61K47/6855 , A61K47/6857 , A61K47/6869 , C07K16/2863 , C07K16/3061 , A61K2039/505
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
公开(公告)号:US20180326084A1
公开(公告)日:2018-11-15
申请号:US15742818
申请日:2016-07-08
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Kirstine JACOBSEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Henrik Jørn DITZEL , Paul PARREN
CPC classification number: A61K47/6803 , A61K39/001102 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61K2039/505 , A61P35/00 , C07K16/2863 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
-
公开(公告)号:US20170355767A1
公开(公告)日:2017-12-14
申请号:US15541594
申请日:2016-01-08
Applicant: GENMAB A/S
Inventor: Patrick ENGELBERTS , Esther BREIJ , Rik RADEMAKER , Isil ALTINTAS , David SATIJN , Sandra VERPLOEGEN , Riemke VAN DIJKHUIZEN RADERSMA , Edward VAN DEN BRINK , Janine SCHUURMAN , Paul PARREN
IPC: C07K16/28 , A61K39/395
CPC classification number: C07K16/2809 , A61K39/39558 , A61K2039/505 , C07K16/2887 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/90 , C07K2317/92 , C07K2317/94
Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
-
公开(公告)号:US20190275149A1
公开(公告)日:2019-09-12
申请号:US16248402
申请日:2019-01-15
Applicant: GENMAB A/S
Inventor: Esther BREIJ , David SATIJN , Edward Norbert VAN DEN BRINK , Dennis VERZIJL , Rob N. DE JONG , Paul PARREN , Riemke VAN DIJKHUIZEN RADERSMA
IPC: A61K39/395 , C07K16/28 , C07K16/30 , A61K47/68
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
公开(公告)号:US20190022243A1
公开(公告)日:2019-01-24
申请号:US16069395
申请日:2017-01-13
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Paul PARREN
Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
-
公开(公告)号:US20180214549A1
公开(公告)日:2018-08-02
申请号:US15938961
申请日:2018-03-28
Applicant: GENMAB A/S
Inventor: Esther BREIJ , David SATIJN , Edward Norbert VAN DEN BRINK , Dennis VERZIJL , Rob N. DE JONG , Paul PARREN , Riemke VAN DIJKHUIZEN RADERSMA
IPC: A61K39/395 , C07K16/30
CPC classification number: A61K39/39558 , A61K47/6801 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61K2039/505 , A61K2121/00 , C07K16/2863 , C07K16/3061 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
公开(公告)号:US20230321261A1
公开(公告)日:2023-10-12
申请号:US17957302
申请日:2022-09-30
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Paul PARREN
CPC classification number: A61K47/6803 , A61K39/001102 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61P35/00 , C07K16/2863 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
-
公开(公告)号:US20200171152A1
公开(公告)日:2020-06-04
申请号:US16673383
申请日:2019-11-04
Applicant: GENMAB A/S
Inventor: Esther BREIJ , David SATIJN , Edward Norbert VAN DEN BRINK , Dennis VERZIJL , Rob N. DE JONG , Paul PARREN , Riemke VAN DIJKHUIZEN RADERSMA
IPC: A61K39/395 , C07K16/28 , A61K47/68 , C07K16/30
Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
公开(公告)号:US20170157250A1
公开(公告)日:2017-06-08
申请号:US15325364
申请日:2015-07-10
Applicant: GENMAB A/S
Inventor: Esther BREIJ , David SATIJN , Edward Norbert VAN DEN BRINK , Dennis VERZIJL , Rob N. DE JONG , Paul PARREN , Riemke VAN DIJKHUIZEN RADERSMA
IPC: A61K39/395 , C07K16/30
Abstract: The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
-
-
-
-
-
-
-
-